Access For Life

Access for Life aims to facilitate repetitive therapies requiring vascular access for patients with chronic diseases. The companys patented JEM device acts as a smart needle guide and is designed to preserve the vessel wall and reduce the rate of clinical complications due to vessel wall damage (e.g. perforation, pseudoaneurysms, hematomas, and infection), reducing morbidity and mortality as well as healthcare costs. The device is designed to allow for easier and safer repetitive vascular access, particularly for hemodialysis and eventually for chemotherapy. The JEM smart device attaches directly to an arterio-venous (AV) fistula or graft and is implanted in the subcutaneous tissue directly beneath the skin. It provides safer and easier repeated insertion of needles for vascular access and prevents unintended vein perforation and bleeding. The device requires much less skill for proper needle insertion, encourages home and self-care hemodialysis, and can use a blunt needle for pain reduction. It could also replace the chemoport currently used for chemotherapy. In addition, Access for Life has added sensors which allow ultrasound and velocity measurements to provide clinical data to clinicians and patients and to enable dialysis-related big data analysis.

Access For Life was founded in 2013 by Roger Mason (Founder & CMO).

Access For Life operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances, Implants, Sensing. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients.

Access For Life is based in HaGra 11, Netanya, Israel, Center District. The company also has offices abroad.